Search research articles
Contact Us
Filters
Showing results (21-30 of 173) with videos related to
Page
of 18
Sort By:
Nature Reviews. Disease Primers
|
December 10, 2021
Endometrial cancer
Vicky Makker, Helen MacKay, Isabelle Ray-Coquard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 3, 2025
Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis
Guillermo Villacampa, Gemma Eminowicz, Victor Navarro, et al.
Clinical Advances in Hematology & Oncology : H&O
|
April 8, 2024
Immunotherapy in the treatment of advanced or recurrent endometrial cancer
Juan Francisco Grau-Bejar, Lorena Farinas-Madrid, Carmen García-Duran, et al.
Cancer Treatment Reviews
|
February 29, 2024
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
Michele Bartoletti, Marcella Montico, Domenica Lorusso, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
February 5, 2010
CA-125 response patterns in patients with recurrent ovarian cancer treated with pegylated liposomal doxorubicin (PLD)
Ana Oaknin, Pilar Barretina, Xavier Pérez, et al.
Investigational New Drugs
|
July 13, 2010
Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas
Ramón Salazar, Ruth Plummer, Ana Oaknin, et al.
Future Oncology (London, England)
|
February 10, 2018
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer
Kathleen N Moore, Ignace Vergote, Ana Oaknin, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 20, 2022
Novel Therapies in Gynecologic Cancer
Francisco Grau Bejar, Ana Oaknin, Casey Williamson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2026
Post-Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Vicky Makker, Jung-Yun Lee, Do-Youn Oh, et al.
The Oncologist
|
June 30, 2021
Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
Vicky Makker, Matthew H Taylor, Ana Oaknin, et al.
Page
of 18
Search research articles
Search
Showing results (21-30 of 173) with videos related to
Sort By:
Page
of 18
Nature Reviews. Disease Primers
|
December 10, 2021
Endometrial cancer
Vicky Makker, Helen MacKay, Isabelle Ray-Coquard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 3, 2025
Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis
Guillermo Villacampa, Gemma Eminowicz, Victor Navarro, et al.
Clinical Advances in Hematology & Oncology : H&O
|
April 8, 2024
Immunotherapy in the treatment of advanced or recurrent endometrial cancer
Juan Francisco Grau-Bejar, Lorena Farinas-Madrid, Carmen García-Duran, et al.
Cancer Treatment Reviews
|
February 29, 2024
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
Michele Bartoletti, Marcella Montico, Domenica Lorusso, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
February 5, 2010
CA-125 response patterns in patients with recurrent ovarian cancer treated with pegylated liposomal doxorubicin (PLD)
Ana Oaknin, Pilar Barretina, Xavier Pérez, et al.
Investigational New Drugs
|
July 13, 2010
Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas
Ramón Salazar, Ruth Plummer, Ana Oaknin, et al.
Future Oncology (London, England)
|
February 10, 2018
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer
Kathleen N Moore, Ignace Vergote, Ana Oaknin, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 20, 2022
Novel Therapies in Gynecologic Cancer
Francisco Grau Bejar, Ana Oaknin, Casey Williamson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2026
Post-Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Vicky Makker, Jung-Yun Lee, Do-Youn Oh, et al.
The Oncologist
|
June 30, 2021
Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
Vicky Makker, Matthew H Taylor, Ana Oaknin, et al.
Page
of 18